DUBLIN, Ireland (

TheStreet

) --

Covidien

(COV)

beat profit and revenue expectations on stronger sales of its medical devices.

Covidien said early Tuesday it booked a 47% increase in third-quarter earnings to $535 million, or $1.07 a share, compared with year-earlier earnings of $364 million, or 72 cents a share. Excluding one-time items, earnings came to $1.01 a share. Net revenue grew 14% to $2.93 billion.

Analysts had expected Covidien to earn 95 cents a share on revenue of $2.86 billion.

Covidien, which makes surgical products, drugs and medical supplies, said its medical device division posted a 22% jump in sales to $1.99 billion. Its pharmaceutical unit saw revenue fall 1% to $500 million as sales of branded specialty drugs were slower.

Shares of Covidien rose 5.3% in premarket trading Tuesday after the stock closed lower at $50.25 in Monday's session.

>> J&J: Pharma, Pipeline Driving Growth

Medical device and drug maker

Johnson & Johnson

(JNJ) - Get Report

beat earnings expectations last week and said its pharmaceutical division continued to reinvigorate its growth profile.

In its recent quarter, J&J's pharma division saw sales increase by 12.3% to $6.23 billion. J&J pharmaceutical unit competes with other major drugmakers such as

Pfizer

(PFE) - Get Report

,

Merck

(MRK) - Get Report

and

Novartis

(NVS) - Get Report

.

J&J also saw sales gains in its other two divisions, medical devices and consumer products, the latter of which suffered a series of embarrassing

product recalls for popular medicines like Tylenol, Motrin and Rolaids

.

>> 2011 Consumer Recall Alerts

J&J's medical devices unit, where it competed with

Abbott Laboratories

(ABT) - Get Report

in the stent market before closing down those operations, but still competes with orthopedic replacement makers

Stryker

(SYK) - Get Report

and

Zimmer

(ZMH)

, saw a sales increase of 7.2% to $6.57 billion.

Because of its wide range of diversification within the health care, biotechnology and drug sectors, J&J is widely considered an industry bellwether.

>>For upcoming earnings and estimates, see our

Earnings Calendar

.

--

Written by Miriam Marcus Reimer in New York.

>To contact the writer of this article, click here:

Miriam Reimer

.

>To follow the writer on Twitter, go to

http://twitter.com/miriamsmarket

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

READERS ALSO LIKE:

>> Don't Buy Dunkin' Donuts IPO: Value Analyst

>> Bankruptcy Watch: 14 Risky Restaurant Stocks

>> Consumer Dividend Stocks Increasing Payouts

>> 14 REITs Increasing Dividends Annually

>> Taco Bell to Offer Free Wi-Fi by 2015

>> Starbucks to Grow Grocery Business Tenfold

>>See our new stock quote page.

Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.